Targeting LSD1 for acute myeloid leukemia (AML) treatment

• Published in: Pharmacological research Vol. 164; p. 105335
• Main Authors: Zhang, Shujing, Liu, Menghan, Yao, Yongfang, Yu, Bin, Liu, Hongmin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.02.2021
• Subjects: AML treatment; Combination therapy; Histone demethylase; LSD1 inhibitors; Tranylcypromine derivatives; AML treatment; Histone demethylase; LSD1 inhibitors; Combination therapy; Tranylcypromine derivatives
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2020.105335

[Display omitted] Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently there are very limited therapeutic targets for AML treatment. Histone lysine specific demethylase 1 (LSD1) is highly expressed in many cancers, impedes the differentiation of cancer cells, promotes the proliferation, metastasis and invasion of cancer cells, and is associated with poor prognosis. Targeting LSD1 has been recognized as a promising strategy for AML treatment in recent years. Based on these features, in the review, we discussed the main epigenetic drugs targeting LSD1 for AML therapy. Thus, this review focuses on the progress of LSD1 inhibitors in AML treatment, particularly those such as tranylcypromine (TCP), ORY-1001, GSK2879552, and IMG-7289 in clinical trials. These inhibitors provide novel scaffolds for designing new LSD1 inhibitors. Besides, combined therapies of LSD1 inhibitors with other drugs for AML treatment are also highlighted.